Wholesale Pharma Peptides 5 Mg CAS 910463-68-2 Semaglutide Used in Loss Weight

Model NO.
HRK-Semaglutide
Colour
White
Test
HPLC
Grade Standard
Pharmaceutical Grade
Certificate
GMP ISO USP Bp
Storage
Cool Dry Place
Shelf Life
2 Years Proper Storage
Assay
99.9% Min
Type of Product
Cosmetic
CAS No
910463-68-2
Einecs No
203-405-2
MW
4113.57754
Mf
C187h291n45o59
Product Name
Semaglutide
Transport Package
1kg Per Bag
Specification
99% min Semaglutide
Trademark
Henrikang
Origin
Shaanxi China
Production Capacity
5000kg/Year
Reference Price
$ 45.00 - 90.00
Contact Us

Product Description

Wholesale Pharma Peptides 5 Mg CAS 910463-68-2 Semaglutide Used in Loss Weight

Wholesale Pharma Raw Peptides 5 mg CAS 910463-68-2 Semaglutide Used in Loss Weight

Product Name
Wholesale Pharma Raw Peptides 5 mg CAS 910463-68-2 Semaglutide Used in Loss Weight
CAS NO
910463-68-2
Appearance
White Powder
Molecular Formula
C187H291N45O59
Storage
Keep in a cool, dry, dark location
Shelf Life
24 months when properly stored
Wholesale Pharma Peptides 5 Mg CAS 910463-68-2 Semaglutide Used in Loss Weight
Sommarutide is a long-acting formulation based on the basic structure of Liraglutide, which is more effective in the treatment of type 2 diabetes. Sommarutide was prepared by solid-liquid synthesis method. Linear peptide Aib8, Arg34GLP-1(7-37) and aliphatic acylating agent were prepared by solid-phase synthesis. Under alkaline conditions, the synthetic aliphatic acylating agent was used to modify the linear peptide Lys26 to obtain sommaruteptide. The biological activity of the self-made samples was determined by time-resolved fluorescence resonance energy transfer immunoassay.
Wholesale Pharma Peptides 5 Mg CAS 910463-68-2 Semaglutide Used in Loss Weight
semaglutide is a long-acting formulation based on the basic structure of Liraglutide, which is more effective in the treatment of type 2 diabetes. Novo Nordisk has completed six PhaseIIIa studies for its Sommarutide injection and has submitted a New drug registration application for its weekly injection to the US Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) on 5 December 2016. A once-daily oral formulation of Sommarutide, on the other hand, is currently in phase III.


Wholesale Pharma Peptides 5 Mg CAS 910463-68-2 Semaglutide Used in Loss Weight

Wholesale Pharma Peptides 5 Mg CAS 910463-68-2 Semaglutide Used in Loss Weight
Wholesale Pharma Peptides 5 Mg CAS 910463-68-2 Semaglutide Used in Loss Weight


 

 

Organic Intermediate